{"name":"APRINOIA Therapeutics, LLC","slug":"aprinoia-therapeutics-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"APNmAb005","genericName":"APNmAb005","slug":"apnmab005","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"APNmAb005","genericName":"APNmAb005","slug":"apnmab005","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNYjJ6NGZKY1gxYS1oWTFMTnRBVUt3N1pUdnd3VHg3U2ZmRl9qWWlOVWp6TzQzdVBKSHpZWjJmVV94TVJVelBIN1JUUzNvWlRCWXIxYzRtSUdCbkhwM1FSRDZMaGJlYVdleUxkSS1SWTFwc1k3T3dWZk9TbTFuTjdnLVBrRkdEaUZWSjU2ajkwNHF3TDJPZWdpb2VLUU9PSHZHeUk1ekMyQlJmWW1XWG9KTVZVNWp1SEJjRFBVZWNCTFRNaV82Q2tRaEUtR0RZQQ?oc=5","date":"2024-02-26","type":"pipeline","source":"renaissancecapital.com","summary":"APRI IPO News - Neurodegenerative disease biotech APRINOIA Therapeutics sets terms for $24 million IPO - renaissancecapital.com","headline":"APRI IPO News - Neurodegenerative disease biotech APRINOIA Therapeutics sets terms for $24 million IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNWlJVN3B2d09RVGI1QXJuN1hibTUwdFNZeXpjZjJ2ZHplbTlOczRfZjlDa2VMR1RhSWtJSG5FT0FhSWFWVjB1SHhucGdFUU43MGcwTlY4TTJEY3lqT3hfYVlfcmFKcFlyTVpoNUU2VUFSenlnVDRuX3BMdEl3anRaQXNndjN5cVFRMWhwcllxTGUwcVpUVThKY0ZLWl9RX1U5WFZQSXc0TTlXbFRoTlNyLWg3S194dFVKdzVZYU9HM3NSRmlueDVncnl6NXBuZw?oc=5","date":"2024-01-26","type":"pipeline","source":"renaissancecapital.com","summary":"APRI IPO News - Neurodegenerative disease biotech APRINOIA Therapeutics files for a $50 million IPO - renaissancecapital.com","headline":"APRI IPO News - Neurodegenerative disease biotech APRINOIA Therapeutics files for a $50 million IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNVVM3NEdiU2Vma1paY0tpWWRtQ1VyRXpvS09ieklZbmk2dXpJRU81cFZTZWQ0ZlhFRkZ2ajM2SE1TZjdfaE9iMm04ejB2M2k2NGpFMk1OQVhIa29ac1VYc3d5dXhnRkd3eXJaWmh4X0JGQzhUenVsZHRyZnhpakZFUjJSVnc3TVl6UlU0Uy1rd2VKUQ?oc=5","date":"2023-04-18","type":"pipeline","source":"drugdiscoverytrends.com","summary":"The future of neurodegenerative disease research: AI, PET tracers - drugdiscoverytrends.com","headline":"The future of neurodegenerative disease research: AI, PET tracers","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}